This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Wright Medical (WMGI) Posts Wider-than-Expected Loss in Q1
by Zacks Equity Research
Wright Medical Group N.V. (WMGI) reported adjusted loss of 9 cents per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 8 cents.
PerkinElmer (PKI) Tops Q1 Earnings Estimates, FY17 View Up
by Zacks Equity Research
PerkinElmer Inc (PKI) reported first-quarter 2017 adjusted earnings of 55 cents per share, marginally beating the Zacks Consensus Estimate by a penny.
athenahealth (ATHN) Earnings, Revenues Miss Estimates in Q1
by Zacks Equity Research
athenahealth Inc. (ATHN) reported adjusted earnings of 10 cents per share in the first quarter of fiscal 2017.
AmerisourceBergen (ABC) Beats on Q2 Earnings, Lags Revenues
by Zacks Equity Research
AmerisourceBergen Corporation (ABC) posted adjusted earnings of $1.77 per share in the second quarter of fiscal 2017, beating the Zacks Consensus Estimate of $1.71 and increasing 5.4% on a year-over-year basis.
Cardiovascular Systems (CSII) Swings to Earnings in Q3
by Zacks Equity Research
Cardiovascular Systems, Inc. (CSII) reported adjusted earnings per share of 3 cents in third-quarter fiscal 2017, reflecting a massive improvement from the year-ago quarter's adjusted loss of 47 cents.
Bruker (BRKR) Q1 Earnings Meet, Revenues Beat Estimates
by Zacks Equity Research
Bruker Corporation (BRKR) reported adjusted earnings per share (EPS) of 19 cents in the first quarter of 2017, lower than the year-ago figure by 9.5%.
DaVita (DVA) Earnings Miss Estimates, Revenues Beat in Q1
by Zacks Equity Research
DaVita Inc. (DVA) reported first-quarter 2017 adjusted operating earnings of 79 cents per share that missed the Zacks Consensus Estimate of 82 cents.
QIAGEN (QGEN) Beats Q1 Earnings Estimates, Retains View
by Zacks Equity Research
QIAGEN N.V. (QGEN) reported first-quarter 2017 adjusted earnings per share (considering restructuring expenses as one time item) of 22 cents, up 15.8% year over year.
DexCom (DXCM) Q1 Loss Narrower than Expected, Revenues Miss
by Zacks Equity Research
DexCom Inc. (DXCM) reported a loss of 49 cents per share in the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 55 cents.
Myriad Genetics (MYGN) Tops Q3 Earnings & Sales, Tweaks View
by Zacks Equity Research
Myriad Genetics Inc. (MYGN) reported adjusted earnings per share (EPS) of 27 cents in the third quarter of fiscal 2017, down 34% year over year.
Amedisys (AMED) Beats on Q1 Earnings, Revenues Meet Mark
by Zacks Equity Research
Amedisys Inc. (AMED) reported adjusted earnings from continuing operations of 47 cents per share in the first quarter of 2017, up 42.4% year over year.
CVS Health (CVS) Q1 Earnings Beat Estimates, Decrease Y/Y
by Zacks Equity Research
CVS Health Corporation (CVS) reported first-quarter 2017 adjusted earnings per share (EPS) of $1.17, down 0.8% year over year.
Ecolab (ECL) Q1 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
Ecolab Inc. (ECL) reported first-quarter 2017 adjusted earnings (excluding special gains, charges and tax items) of 80 cents per share, which missed the Zacks Consensus Estimate of 81 cents.
Becton, Dickinson (BDX) Q2 Earnings Beat, Increase Y/Y
by Zacks Equity Research
Becton, Dickinson and Company (BDX), popularly known as BD, reported second-quarter fiscal 2017 earnings of $2.30 per share, which beat the Zacks Consensus Estimate of $2.23 and increased 5.5% on a year-over-year basis.
Luminex (LMNX) Tops Q1 Earnings, Revenue Guidance Raised
by Zacks Equity Research
Luminex Corporation (LMNX) reported earnings of 27 cents per share in the first quarter of 2017, surpassing the Zacks Consensus Estimate of adjusted earnings of 8 cents per share by a massive 237.5%.
Cardinal Health (CAH) Q3 Earnings Beat Estimates, Rise Y/Y
by Zacks Equity Research
Cardinal Health Inc. (CAH) reported third-quarter fiscal 2017 adjusted earnings of $1.53 per share, which beat the Zacks Consensus Estimate of $1.46 and increased 7% on a year-over-year basis.
Hill-Rom (HRC) Beats Earnings & Revenue Estimates in Q2
by Zacks Equity Research
Hill-Rom Holdings, Inc. (HRC) reported second-quarter fiscal 2017 adjusted earnings per share (EPS) of 88 cents, up 23.9% from the year-ago quarter.
Accuray (ARAY) Incurs Loss in Q3, Revenues Miss Estimates
by Zacks Equity Research
Accuray Inc.(ARAY) reported a loss of 6 cents per share in the third quarter of fiscal 2017, comparing unfavorably with the Zacks Consensus Estimate of earnings of a penny.
Is a Surprise in Store for Hologic (HOLX) in Q2 Earnings?
by Zacks Equity Research
Hologic Inc. (HOLX) is slated to report second-quarter fiscal 2017 financial results on May 10, after the closing bell.
Align Technology (ALGN) Beats on Q1 Earnings and Revenues
by Zacks Equity Research
Align Technology Inc. (ALGN) reported adjusted earnings per share (EPS) of 85 cents in the first quarter of 2017, up 70% from 50 cents posted in the year-ago quarter.
athenahealth (ATHN) Misses on Earnings & Revenues in Q1
by Zacks Equity Research
athenahealth Inc. (ATHN) reported adjusted earnings of 10 cents per share in the first quarter of fiscal 2017, which missed the Zacks Consensus Estimate by a penny.
Chemed's (CHE) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Chemed Corp.'s (CHE) first-quarter 2017 adjusted earnings per share (EPS) (considering stock-based compensation expense and related tax benefit as a regular one) were $1.92, as compared to the year-ago adjusted EPS figure of $1.52, up 26.3% year over year.
Varian Medical (VAR) Beats on Earnings and Revenues in Q2
by Zacks Equity Research
Varian Medical Systems, Inc. (VAR) reported adjusted earnings of 89 cents per share in the second quarter of fiscal 2017, which beat the Zacks Consensus Estimate by a penny.
Pacific Biosciences (PACB) Q1 Loss Wider than Estimated
by Zacks Equity Research
Pacific Biosciences of California Inc. (PACB) reported a loss of 26 cents per share in the first quarter of 2017. The figure is 3 cents wider than the Zacks Consensus Estimate.
Baxter International (BAX) Q1 Earnings Beat, FY17 View Up
by Zacks Equity Research
Baxter International Inc. (BAX) reported first-quarter 2017 adjusted earnings of 58 cents per share, which surpassed the Zacks Consensus Estimate by 7 cents and was way better than the year-ago figure of 36 cents.